COMPANION DIAGNOSTIC FOR CUTANEOUS AND UVEAL MELANOMA
Lack of uveal melanoma non-invasive treatment and predictive metastasis progresion
- A Prognostic Test to Predict the Risk of Metastasis in Uveal and Cutaneous Melanoma
- A combination drug therapy for both diseases
Prognostic biomarker for cutaneous and uveal melanoma
Combination therapy for metastatic melanoma
Inhibition of metastasis and survival of cancer Stem Cells
The invention could be used as a companion diagnostic to help healthcare professionals determine the best therapeutic option for melanoma patients. Doctors could know in advance which patients would probably develop metastasis.
As well as, they would have an alternative treatment for those patients that do not have the BRAF V600 mutation or for patients resistant to Vemurafenib.
A group of exosomal miRNAs, which are present in blood and lymphatic torrent of melanoma patients, have been identified as good predictor markers of metastasis. Clinicians of HUB, who have collected blood and plasma samples of patients at different stages of their cancer progression, are now validating these markers.
Through an in vitro screening, the research group has selected two proteins as potential inhibitors of tumor progression. These proteins target several signaling pathways related to metastasis and also inhibit the survival of cancer Stem Cells.
TRL: Experimental PoC
IP: Patent on draft